TSHA

3.7051.72%
KA

Kamran Alam

CFO & Corporate Secretary

Mr. Kamran Alam, C.P.A., M.B.A., serves as Treasurer at Huntington's Disease Society Of America, Inc. He is Chief Financial Officer at Taysha Gene Therapies, Inc since August 2020 and serves as its Corporate Secretary. He had been Senior Vice President of Finance and Principal Financial Officer of Rocket Pharmaceuticals, Inc. since October 28, 2019 until July 2020. He has experience in the biotechnology industry. He is Finance executive with follow-on financings and M&A experience. He was Vice President, Finance at AveXis, Inc from April 2016 to October 2019 where he established and built a finance team. While at AveXis, he led Financial Planning and Analysis, Procurement and Risk Management functions. Following Novartis’ acquisition of AveXis, he was appointed Deputy Chief Financial Officer and supported the development and commercialization of Zolgensma and advancement of AveXis’ gene therapy pipeline programs. He also played a key role in the acquisition of AveXis by Novartis. His prior biotech industry experiences include Senior Director, Finance and Accounting at Aptinyx from August 2015 to April 2016, where he held a leadership role in the finance and accounting team. From March 2013 to August 2015, he was also Director of Finance at Naurex, culminating in Allergan’s acquisition of Naurex. Earlier in his career, he held various finance and project management roles with increasing responsibility at Ovation Pharmaceuticals, Lundbeck and Fresenius Kabi. He received his Bachelor of Business Administration degree with High Distinction from the Ross School of Business at University of Michigan and MBA in Finance from the Kelley School of Business at Indiana University. He is a Certified Public Accountant. He is on the Board of Trustees at Huntington’s Disease Society of America (HDSA). He is passionate about working at organizations that focus on innovative, life-saving new therapies to help people lead longer and healthier lives.

Positions